Bronchodilator Drugs - China | Statista Market Forecast

in China, one of the key players in the global pharmaceutical industry, is projected to witness significant growth in the Bronchodilator Drugs market.
According to market projections, the revenue in this market is expected to reach US$3.35bn by 2024.
The market is expected to maintain a steady growth rate of 4.28% annually from 2024 to 2029, resulting in a market volume of US$4.13bn by the end of 2029.
It is worth noting that United States is anticipated to generate the highest revenue in this market, amounting to US$17.34bn in 2024.
China's growing middle class and increasing air pollution levels are driving the demand for bronchodilator drugs in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are in high demand in China due to the high prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). These drugs are used to relax the muscles in the airways, allowing for easier breathing. The Bronchodilator Drugs market in China is experiencing steady growth due to various factors.

Customer preferences: Chinese customers prefer using bronchodilator drugs as a first-line treatment for respiratory diseases. This is due to the ease of use and fast relief of symptoms provided by these drugs. In addition, the increasing awareness of the importance of early diagnosis and treatment of respiratory diseases is driving the demand for bronchodilator drugs.

Trends in the market: The Bronchodilator Drugs market in China is witnessing a shift towards combination therapies. Combination therapies are becoming increasingly popular as they offer better control of symptoms and reduce the need for multiple medications. In addition, the market is also seeing an increase in the demand for long-acting bronchodilators, which provide sustained relief of symptoms.

Local special circumstances: China has a high prevalence of respiratory diseases due to air pollution, smoking, and other environmental factors. This has led to a high demand for bronchodilator drugs in the country. In addition, the Chinese government's efforts to improve healthcare infrastructure and increase access to healthcare services are also driving the growth of the market.

Underlying macroeconomic factors: China's rapidly aging population is driving the demand for bronchodilator drugs. As the population ages, the prevalence of respiratory diseases is expected to increase, leading to a higher demand for these drugs. In addition, the increasing disposable income of the middle-class population in China is also driving the growth of the market. The middle-class population has greater access to healthcare services and is more willing to spend on healthcare products.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.